Amicus Therapeutics Net Income Over Time
| FOLD Stock | USD 14.34 0.04 0.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Amicus Therapeutics Performance and Amicus Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Amicus diversify its offerings? Factors like these will boost the valuation of Amicus Therapeutics. Market participants price Amicus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amicus Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.04) | Revenue Per Share | Quarterly Revenue Growth 0.195 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Amicus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Amicus Therapeutics and related stocks such as Ideaya Biosciences, Scholar Rock Holding, and Adaptive Biotechnologies Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| ADPT | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (46.4 M) | (68.6 M) | (146.2 M) | (207.3 M) | (200.2 M) | (225.2 M) | (159.5 M) | (59.5 M) | (62.5 M) |
| ARQT | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (19.3 M) | (42 M) | (135.7 M) | (205.9 M) | (311.5 M) | (262.1 M) | (140 M) | (126 M) | (132.3 M) |
| CDTX | (792 K) | (792 K) | (792 K) | (1.3 M) | (11.9 M) | (32.2 M) | (48.2 M) | (55.7 M) | (59 M) | (41.1 M) | (72.1 M) | (43.9 M) | (29.8 M) | (22.9 M) | (169.8 M) | (152.8 M) | (145.2 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (177.8 M) | (160 M) | (152 M) |
| KNSA | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (64.9 M) | (103.2 M) | (161.9 M) | (161.4 M) | (157.9 M) | 183.4 M | 14.1 M | (43.2 M) | (49.7 M) | (52.2 M) |
| TARS | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (4.7 M) | (26.8 M) | (13.8 M) | (62.1 M) | (135.9 M) | (115.6 M) | (104 M) | (98.8 M) |
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | (2.8 M) | (101.6 M) | (266.4 M) | (403.6 M) | (446.3 M) | (518.3 M) | (177 M) | (159.3 M) | (167.3 M) |
| CPRX | (255.9 K) | (6.4 M) | (4.1 M) | (12.2 M) | (15.5 M) | (20.2 M) | (18.1 M) | (18.4 M) | (34 M) | 31.9 M | 75 M | 39.5 M | 83.1 M | 71.4 M | 163.9 M | 188.5 M | 197.9 M |
Amicus Therapeutics and related stocks such as Ideaya Biosciences, Scholar Rock Holding, and Adaptive Biotechnologies Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Amicus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Amicus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Amicus Therapeutics | FOLD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 47 Hulfish Street, |
| Exchange | NASDAQ Exchange |
USD 14.34
Check out Amicus Therapeutics Performance and Amicus Therapeutics Correlation. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Amicus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.